New hope for rare fat disorder: experimental drug mibavademab under safety review
NCT ID NCT06548100
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This study tests the safety of switching from the current drug metreleptin to a new experimental drug called mibavademab in people with generalized lipodystrophy, a rare condition where the body cannot properly store fat. Nine participants who have been stable on metreleptin will receive mibavademab and be monitored for side effects, blood levels, and how their body responds. The goal is to see if this new drug is a safe alternative.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mibavademab (also called REGN4461), a leptin receptor agonist antibody
- What this could lead to
- If successful, mibavademab could offer a new treatment option for generalized lipodystrophy, potentially replacing the current therapy metreleptin.
- What could go wrong
- This is a very small early-phase safety study with only 9 participants, so results may not apply to everyone. The drug may cause side effects or not work as well as the current treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health
Bethesda, Maryland, 20892, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.